Page 7,043«..1020..7,0427,0437,0447,045..7,0507,060..»

$3.7 Billion Market for Parkinson’s Drugs Could Prove Key to RBCC’s Growth

Posted: Published on March 6th, 2012

NOKOMIS, Fla.--(BUSINESS WIRE)-- As demand for effective diagnostics and treatments for Parkinsons Disease grows around the globe, Rainbow BioSciences (OTCBB: RBCC.OB - News) is working to capitalize by helping to deliver promising new therapies to market. RBCC announced today that the company plans to sign a letter of intent with a drug development company that could be on the verge of promising new diagnostic and therapeutic tools for Parkinsons patients and their doctors. The increasing market potential for Parkinsons therapies is what attracted RBCCs attention to the developing company. The market for Parkinson's disease drugs could grow to a value of $3.75 billion by 2015, according to a report last year by Visiongain. Growth in the Parkinson's treatment market is being driven by new breakthroughs, and RBCC could potentially help advance the timeline for a cure for the debilitating disease. RBCC plans to continue discussing deals with emerging drug therapy companies in an effort to speed that cure along. For more information on RBCCs biotechnology initiatives, please visit http://www.rainbowbiosciences.com/investors. About Rainbow BioSciences Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC.OB - News). The company continually seeks out new partnerships with biotechnology developers to deliver … Continue reading

Posted in Parkinson's Treatment | Comments Off on $3.7 Billion Market for Parkinson’s Drugs Could Prove Key to RBCC’s Growth

QR Pharma Awarded Funding by Michael J. Fox Foundation to Test Posiphen® as a Treatment for Parkinson’s Disease

Posted: Published on March 6th, 2012

BERWYN, Pa.--(BUSINESS WIRE)-- QR Pharma, Inc. (QR) a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimers disease, Parkinsons disease (PD) and other neurodegenerative disorders, announced today that The Michael J. Fox Foundation for Parkinsons Research (MJFF) awarded the company $468,000 to conduct research for the development of Posiphen to treat PD. QR will collaborate with Robert Nussbaum, MD, Professor, Department of Medicine and Chief, Division of Medical Genetics at the University of California, San Francisco and Jack T. Rogers, PhD, Associate Professor Psychiatry (Neuroscience) at the Massachusetts General Hospital, Genetics and Aging Research Unit. Mutations and overexpression of alpha-synuclein (a-SYN) have been shown to cause familial PD while genetic association studies indicate a-SYN is a key risk factor in sporadic PD. Evidence suggests that therapies that can reduce a-SYN expression may block its pathogenic actions and therefore be useful in treating PD. In vitro studies conducted at Massachusetts General Hospital demonstrate that Posiphen lowers a-SYN levels by inhibiting a-SYN translation. To establish efficacy in PD, Posiphen will be tested in transgenic mice engineered by Dr. Nussbaums group at UCSF that express mutant human a-SYN. These mice exhibit early gastrointestinal dysfunction at … Continue reading

Posted in Parkinson's Treatment | Comments Off on QR Pharma Awarded Funding by Michael J. Fox Foundation to Test Posiphen® as a Treatment for Parkinson’s Disease

Uncertainty over NHS reforms threatens future of world leading cerebal palsy centre

Posted: Published on March 6th, 2012

Boyle family (L-R Patricia Boyle, Steven Boyle and their son Thomas Boyle) by Sarah Collings, Reporter Tuesday, March 6, 2012 7:05 AM A question mark hangs over the future of a world-renowned centre that provides care and hope for children with cerebral palsy. To send a link to this page to a friend, simply enter their email address below. The message will include the name and email address you gave us when you signed up. Send link To send a link to this page to a friend, you must be logged in. The Bobath Centre for Children with Cerebral Palsy, in East End Road, East Finchley, is facing the biggest crisis of its 55-year history due to a drop in funding. Managers claim uncertainty about the outcome of the governments controversial NHS reforms has led to a failure by health authorities to fund patients. Ten-year-old Thomas Boyle has been treated by the Bobath Centre, which was based in Netherhall Gardens, Hampstead, until 1993, every year since he was four years old. Read the original post: Uncertainty over NHS reforms threatens future of world leading cerebal palsy centre … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on Uncertainty over NHS reforms threatens future of world leading cerebal palsy centre

R5.5m claim after baby born with cerebral palsy

Posted: Published on March 6th, 2012

The mother of a five-year-old boy born with cerebral palsy, allegedly because of the negligence of the clinic where her son was delivered, is claiming more than R5.5 million from the Alexandra Health Centre and University Clinic and Gauteng health MEC. Lerato Leba, an unemployed mother from Alexandra, blames her sons condition entirely on the staff at the health centre. She said they made her give birth naturally to Koketso in October 13, leaving her as she endured 17 hours of agonising labour, instead of giving her a Caesarean. She appealed to the nursing staff to transfer her to the Johannesburg General Hospital, but her pleas fell on deaf ears, according to papers before the Pretoria High Court. Her son suffered brain damage during the birth. The health clinic is a welfare organisation that falls under the auspices of the Gauteng health MEC. Leba went to the clinic during her pregnancy, where she was monitored. She was admitted to the clinic on October 11, 2006 with lower abdominal pain, but was discharged that evening after a brief physical examination by a member of the nursing staff. The nurse concluded that Leba was not in labour and so did not have … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on R5.5m claim after baby born with cerebral palsy

Expensive yet Cost-Effective: Aggressive Traumatic Brain Injury Care Improves Outcomes, Reduces Long-Term Costs, Penn …

Posted: Published on March 6th, 2012

PHILADELPHIA Aggressive treatment for severe traumatic brain injuries costs more than routine care, yet yields significantly better outcomes, improved quality of life, and lower long term care costs, according to a new study by researchers in the Perelman School of Medicine at the University of Pennsylvania. For example, in 20 year old traumatic brain injury survivor, aggressive care leads to significantly improved outcomes and costs nearly $100,000 less compared to routine care. Across age groups, the costs of aggressive care were outweighed by the beneficial outcomes and long-term cost savings. The study appears online in the Journal of Neurosurgery. With 1.5 million traumatic brain injuries a year, leading to 200,000 hospitalizations and over 52,000 deaths, the economic costs (direct medical care and loss of productivity) of TBI are estimated to equal $60 billion. This is the first study to demonstrate the cost-effectiveness of intensive TBI care. "This study clearly shows that aggressive care, for both young and older patients who suffer a severe traumatic brain injury, provides patients the best chance at surviving and recovering, and also reduces lifetime costs associated of TBI treatment," said Robert Whitmore, MD, Neurosurgery resident and the study's lead author. Despite effective guidelines from the … Continue reading

Posted in Brain Injury Treatment | Comments Off on Expensive yet Cost-Effective: Aggressive Traumatic Brain Injury Care Improves Outcomes, Reduces Long-Term Costs, Penn …

Irreversible catastrophic brain hemorrhage after minor injury in a patient on dabigatran

Posted: Published on March 6th, 2012

Public release date: 6-Mar-2012 [ | E-mail | Share ] Contact: Gillian Shasby gshasby@thejns.org 434-924-5555 Journal of Neurosurgery Publishing Group Charlottesville, VA (March 6, 2012). Clinicians from the University of Utah report the death of a patient who received a mild brain injury from a ground-level fall while taking the new anticoagulant dabigatran etexilate for nonvalve related atrial fibrillation. The authors describe the events that led from a mild traumatic brain injury to the man's death, the largely irreversible dangers of massive hemorrhage from direct thrombin inhibitors such as dabigatran, and the few management options that can be used to counteract this "uncontrollable" bleeding. Their findings and suggestions can be found in the article "Neurosurgical complications of direct thrombin inhibitorscatastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. Case report," by Drs. Sarah Garber, Walavan Sivakumar, and Richard Schmidt, published online March 6 in the Journal of Neurosurgery. The take-away message is that bleeding complications associated with direct thrombin inhibitors, such as dabigatran, are largely irreversible. Physicians should suspect the strong potential for catastrophic hemorrhage in patients taking these medications so that available, albeit limited, management options can be put into effect without delay. Dabigatran etexilate (Pradaxa) … Continue reading

Posted in Brain Injury Treatment | Comments Off on Irreversible catastrophic brain hemorrhage after minor injury in a patient on dabigatran

Aggressive Brain Injury Care Improves Outcomes, Reduces Costs

Posted: Published on March 6th, 2012

EMBARGOED FOR RELEASE March 6, 2012, 10:00AM ET Expensive yet Cost-Effective: Aggressive Traumatic Brain Injury Care Improves Outcomes, Reduces Long-Term Costs, Penn Study Shows Regardless of Age, Younger and Older Severe TBI Patients Benefit from Aggressive Care Newswise PHILADELPHIA Aggressive treatment for severe traumatic brain injuries costs more than routine care, yet yields significantly better outcomes, improved quality of life, and lower long term care costs, according to a new study by researchers in the Perelman School of Medicine at the University of Pennsylvania. For example, in 20 year old traumatic brain injury survivor, aggressive care leads to significantly improved outcomes and costs nearly $100,000 less compared to routine care. Across age groups, the costs of aggressive care were outweighed by the beneficial outcomes and long-term cost savings. The study appears online in the Journal of Neurosurgery. With 1.5 million traumatic brain injuries a year, leading to 200,000 hospitalizations and over 52,000 deaths, the economic costs (direct medical care and loss of productivity) of TBI are estimated to equal $60 billion. This is the first study to demonstrate the cost-effectiveness of intensive TBI care. "This study clearly shows that aggressive care, for both young and older patients who suffer a … Continue reading

Posted in Brain Injury Treatment | Comments Off on Aggressive Brain Injury Care Improves Outcomes, Reduces Costs

Aggressive traumatic brain injury care improves outcomes, reduces long-term costs

Posted: Published on March 6th, 2012

Public release date: 6-Mar-2012 [ | E-mail | Share ] Contact: Kim Menard kim.menard@uphs.upenn.edu 215-662-6183 University of Pennsylvania School of Medicine PHILADELPHIA Aggressive treatment for severe traumatic brain injuries costs more than routine care, yet yields significantly better outcomes, improved quality of life, and lower long term care costs, according to a new study by researchers in the Perelman School of Medicine at the University of Pennsylvania. For example, in 20 year old traumatic brain injury survivor, aggressive care leads to significantly improved outcomes and costs nearly $100,000 less compared to routine care. Across age groups, the costs of aggressive care were outweighed by the beneficial outcomes and long-term cost savings. The study appears online in the Journal of Neurosurgery. With 1.5 million traumatic brain injuries a year, leading to 200,000 hospitalizations and over 52,000 deaths, the economic costs (direct medical care and loss of productivity) of TBI are estimated to equal $60 billion. This is the first study to demonstrate the cost-effectiveness of intensive TBI care. "This study clearly shows that aggressive care, for both young and older patients who suffer a severe traumatic brain injury, provides patients the best chance at surviving and recovering, and also reduces lifetime … Continue reading

Posted in Brain Injury Treatment | Comments Off on Aggressive traumatic brain injury care improves outcomes, reduces long-term costs

Is aggressive treatment of severe traumatic brain injury cost effective?

Posted: Published on March 6th, 2012

Public release date: 6-Mar-2012 [ | E-mail | Share ] Contact: Gillian Shasby gshasby@thejns.org 434-924-5555 Journal of Neurosurgery Publishing Group Charlottesville, VA (March 6, 2012). Researchers at the Perelman School of Medicine at the University of Pennsylvania have demonstrated that aggressive treatment of severe traumatic brain injury, which includes invasive monitoring of intracranial pressure (ICP) and decompressive craniectomy, produces better patient outcomes than less aggressive measures and is cost-effective in patients no matter their ageeven in patients 80 years of age. These important findings can be found in the article "Is aggressive treatment of traumatic brain injury cost-effective? Clinical article," by Robert Whitmore and colleagues, published online March 6 in the Journal of Neurosurgery. The authors set out to determine whether aggressive treatment of severe traumatic brain injury is cost-effective compared to less aggressive therapeutic approaches. "Severe traumatic brain injury" in this study is defined by a Glasgow Coma Scale score of 8 or less in which the motor component is 5 or less. These researchers created a decisionanalysis model with which they could compare outcomes, costs, and cost-effectiveness of three treatment strategies: 1) comfort care consisting of one day in the intensive care unit followed by continued care in … Continue reading

Posted in Brain Injury Treatment | Comments Off on Is aggressive treatment of severe traumatic brain injury cost effective?

Clinical trials of controversial MS therapy still not OK'd

Posted: Published on March 6th, 2012

Brandon Sun - ONLINE EDITION By: Larry Kusch 6/03/2012 8:27 AM | Comments: 0 MANITOBA is likely still months away from a decision on whether to proceed with clinical trials for a controversial multiple sclerosis treatment. The province and the Manitoba Health Research Council (MHRC) had hoped trials to assess liberation therapy, which involves opening up blocked neck veins, would begin early this year. Premier Greg Selinger announced $5 million in funding toward the research last April. The deadline for research proposals was Sept. 30. Christina Weise, executive director of the MHRC, which would oversee the trials, said her organization hopes to make an announcement by spring. "The review is ongoing and a final decision has not been made," she said in an interview. Weise said the review is being done by a committee of experts who will determine which proposal, if any, best meets the council's criteria. Those include expertise in designing and managing clinical trials, providing care for MS patients and leading a multi-disciplinary, multi-site research team. The task is onerous and there are ethical hurdles, Weise said. To test the procedure, researchers would do a double-blind study consisting of patients who are receiving the treatment and those … Continue reading

Posted in MS Treatment | Comments Off on Clinical trials of controversial MS therapy still not OK'd

Page 7,043«..1020..7,0427,0437,0447,045..7,0507,060..»